{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T21:32:41Z","timestamp":1750109561938},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"the Harbin Applied Technology Research and Development Project","award":["2017RAXXJ073"],"award-info":[{"award-number":["2017RAXXJ073"]}]},{"name":"Hai Yan Foundation of Harbin Medical University Cancer Hospital","award":["JJMS2016-04"],"award-info":[{"award-number":["JJMS2016-04"]}]},{"name":"Wu Jie Ping Medical Foundation Technology Research Project","award":["320.6750.17107"],"award-info":[{"award-number":["320.6750.17107"]}]},{"name":"Heilongjiang Postdoctoral Financial Assistance","award":["LBH-Z16216"],"award-info":[{"award-number":["LBH-Z16216"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.urolonc.2020.07.023","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T05:05:10Z","timestamp":1598072710000},"page":"936.e1-936.e6","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma (mRCC) patients: A single-arm observational study"],"prefix":"10.1016","volume":"38","author":[{"given":"Yan","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muyang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.023_bib0001","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD. Cancer statistics, 2019. 2019;69:7-34.","DOI":"10.3322\/caac.21551"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0002","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wersall","year":"2005","journal-title":"Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0005","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17512433.2017.1386552","article-title":"Multimodal treatment of advanced renal cancer in 2017","volume":"10","author":"Mennitto","year":"2017","journal-title":"Expert review of clinical pharmacology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0006","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/j.clgc.2018.01.016","article-title":"Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis","volume":"16","author":"Ratta","year":"2018","journal-title":"Clinical genitourinary cancer"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2014.04.006","article-title":"A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer","volume":"67","author":"Albiges","year":"2015","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0008","doi-asserted-by":"crossref","unstructured":"Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. 2018;7:4570-83.","DOI":"10.1002\/cam4.1664"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0009","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug design, development and therapy"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molmed.2011.01.015","article-title":"VEGF and angiopoietin signaling in tumor angiogenesis and metastasis","volume":"17","author":"Saharinen","year":"2011","journal-title":"Trends in molecular medicine"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0011","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer science"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0012","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2147\/IJN.S125573","article-title":"Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects","volume":"12","author":"Song","year":"2017","journal-title":"International journal of nanomedicine"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0013","doi-asserted-by":"crossref","first-page":"100734","DOI":"10.18632\/oncotarget.20140","article-title":"Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1073274819872216","article-title":"Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study","volume":"26","author":"Zhang","year":"2019","journal-title":"Cancer control: journal of the Moffitt Cancer Center"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0015","doi-asserted-by":"crossref","unstructured":"Xu J, Liu X, Yang S, Zhang X, Shi Y. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. 2018;14:264-9.","DOI":"10.1111\/ajco.12834"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0016","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ygyno.2017.12.013","article-title":"A phase II study of apatinib in patients with recurrent epithelial ovarian cancer","volume":"148","author":"Miao","year":"2018","journal-title":"Gynecologic oncology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0017","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/1471-2407-14-820","article-title":"Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer","volume":"14","author":"Hu","year":"2014","journal-title":"BMC cancer"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0018","doi-asserted-by":"crossref","first-page":"e9053","DOI":"10.1097\/MD.0000000000009053","article-title":"A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial\/Experimental Study","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0019","first-page":"1175","article-title":"Evolving role of novel targeted agents in renal cell carcinoma","volume":"21","author":"Hutson","year":"2007","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nature reviews Nephrology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0021","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.urolonc.2011.02.012","article-title":"Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"31","author":"Terakawa","year":"2013","journal-title":"Urologic oncology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jchromb.2014.10.013","article-title":"Evaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC-MS\/MS","volume":"973c","author":"Zhou","year":"2014","journal-title":"Journal of chromatography B, Analytical technologies in the biomedical and life sciences"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0023","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1471-2407-10-529","article-title":"Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies","volume":"10","author":"Li","year":"2010","journal-title":"BMC cancer"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0024","doi-asserted-by":"crossref","first-page":"17220","DOI":"10.18632\/oncotarget.7948","article-title":"Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1358\/dot.2015.51.4.2320599","article-title":"Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors","volume":"51","author":"Scott","year":"2015","journal-title":"Drugs of today (Barcelona, Spain: 1998)"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0026","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/IMCRJ.S137484","article-title":"The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature","volume":"10","author":"Bi","year":"2017","journal-title":"International medical case reports journal"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0027","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0028","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11523-019-00653-5","article-title":"Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data","volume":"14","author":"Moran","year":"2019","journal-title":"Targeted oncology"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0029","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clgc.2019.01.018","article-title":"Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma","volume":"17","author":"Procopio","year":"2019","journal-title":"Clinical genitourinary cancer"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.urolonc.2020.07.023_bib0031","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T14:48:16Z","timestamp":1608302896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1078143920303616"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.023","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma (mRCC) patients: A single-arm observational study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}